Protein nanoparticles as drug carriers in clinical medicine.

By M. Hawkins, P. Soon-Shiong, N. Desai. Advanced Drug Delivery Reviews, 2008

736 citations recorded by the source corpus.

Subfields: Biomaterials, Oncology

View Paper: https://www.semanticscholar.org/paper/81c8a309820040f4442fc2fee7c9f685681e8358

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. N. Desai

In Oncology

1. N. Desai

Citations in the corpus

• Challenges in Development of Nanoparticle-Based Therapeutics (2012, background): “Rather than utilizing passive transport via the EPR effect for drug delivery to tumor, nab-paclitaxel relies on active albumin transport pathways including the gp60/caveolae-mediated albumin transcytosis across tumor blood vessel endothelium and potential association with tumoral SPARC to achieve en”
• Smart nanoparticles for cancer therapy (2023, background): “63 The fi rst commercially available drug licensed by the Food and Drug Administration (FDA) that has demonstrated notable ef fi cacy in the treatment of metastatic breast cancer is called Abraxane, which has a diameter of about 130 nm. 12 Cell membrane nanoparticles .”